Related Experiment Video

Updated: Aug 16, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.7K

Comprehensive Analysis of Transcriptomics and Genetic Alterations Identifies Potential Mechanisms Underlying

Zihao Liu1,2, Jingbo Gao1, Ran Gu1

  • 1Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.

Biomolecules
|December 23, 2022
PubMed

Insights

Understanding anthracycline resistance in breast cancer is key. This study identified key gene expression changes and mutations, revealing potential molecular mechanisms for improved treatment strategies.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Anthracyclines are vital for breast cancer treatment.
  • Anthracycline resistance significantly hinders treatment efficacy.
  • Identifying resistance mechanisms is crucial for overcoming treatment failure.

Purpose of the Study:

  • To elucidate the molecular mechanisms of anthracycline resistance in breast cancer.
  • To identify differentially expressed genes and genetic alterations associated with resistance.
  • To explore the role of immune infiltration in anthracycline resistance.

Main Methods:

  • Integration of The Cancer Genome Atlas (TCGA) transcriptome, genetic, and clinical data.
  • Differential gene expression analysis between sensitive and resistant groups.
  • Gene Set Enrichment Analysis (GSEA) and mutation analysis.

Main Results:

  • Identified 204 upregulated and 1376 downregulated genes in resistant vs. sensitive breast cancer.
  • Found upregulation of drug resistance genes (e.g., ABCB5, CYP1A1, CYP4Z1) in resistant tumors.
  • Associated P53 signaling, DNA replication, and metabolism pathways with sensitivity; noted TP53 mutations in sensitive and CDH1 in resistant groups.
  • Observed distinct immune infiltration patterns, with higher immune-related gene expression in the sensitive group.

Conclusions:

  • Uncovered potential molecular drivers of anthracycline resistance in breast cancer.
  • Highlighted the role of specific genes, pathways, and mutations in mediating resistance.
  • Suggested that immune infiltration patterns differ significantly between sensitive and resistant breast cancer, offering therapeutic targets.
Keywords:
anthracyclinebreast cancerresistance

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.3K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
413